General
Preferred name
DOCONEXENT
Synonyms
docosahexaenoic acid ()
Eicosapentaenoic acid/docosa-hexaenoic acid ()
docosahecaenoic Acid, Nectid ()
DHA ()
Cervonic Acid ()
DHA, cervonic acid, doconexent ()
Docosahexaenoic acid (c22:6 n3) ()
Docosahexaenoic acid ()
22:6 n-3 ()
Doconexento ()
Docosaheaenoic-acid ()
Docosahexanoic acid ()
Docosahexaenoate ()
C22:6 (n-3) ()
Docosahexaenoic Acid MaxSpec® Standard ()
Docosahexaenoic Acid 1,2,3,4-13C ()
Docosahexaenoic Acid (peroxide free) ()
P&D ID
PD000826
CAS
6217-54-5
25377-50-8
1024594-51-1
Tags
available
drug
Approved by
FDA
Drug indication
Hypertriglyceridemia
Alzheimer disease
Cardiovascular disease
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Docosahexaenoic acid is an endogenous omega-3 fatty acid, activating all 3 retinoid X receptor isoforms. It has no activity at retinoic acid receptors (RARs), the thyroid hormone receptor or the vitamin D receptor (VDR).
(GtoPdb)
MOA
DHA and its conversion to other lipid signalling moleccules compete with the arachidonic acid cascade from endogenous phospholipids and shift the inflammatory state to being more anti-inflammatory. DHA inhibits endotoxin-stimulated production of IL-6 and IL-8 in human endothelial cells. Derivatives of DHA are anti-inflammatory lipid mediators. Lipid mediators resolvin D1 and protectin D1 all inhibit transendothelial migration of neutrophils, so preventing neutrophilic infiltration at sites of inflammation, resolvin D1 inhibits IL-1β production, and protectin D1 inhibits TNF and IL-1β production [A19356]. Monoxydroxy derivative of DHA converted by LOX inhibit thromboxane-induced platelet aggregation. DHA supplementation has also shown to reduce the levels of serum C-reactive protein (CRP) and other circulating markers of inflammation such as neutrophils in hypertriglyceridemic men [A19438]. ; DHA acts as a ligand at peroxisome proliferator-activated receptor (PPAR) gamma and alpha that regulate lipid signalling molecule-mediated transduction pathways and modulate inflammation. ; As a natural ligand, DHA induces a protective effect in retinal tissues by activating retinoid x receptors and subsequent ERK/MAPK signaling pathway in photoreceptors to promote their survival and differentiation, stimulating the expression of antiapoptotic proteins such as Bcl-2 and preserving mitochondrial membrane potential [A19453].
DESCRIPTION
Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
2
Compound Sets
23
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
328.24
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
14
Ring Count
0
Aromatic Ring Count
0
cLogP
6.55
TPSA
37.3
Fraction CSP3
0.41
Chiral centers
0.0
Largest ring
0.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
PPARalpha Agonists
PPAR receptor agonist
Target
FFAR1, PTGS1, PTGS2
Endogenous Metabolite
Pathway
Metabolic Enzyme/Protease
Source data
